Insider Buying: DiaMedica Therapeutics Inc (NASDAQ:DMAC) Director Buys $20,070.40 in Stock

DiaMedica Therapeutics Inc (NASDAQ:DMAC) Director Richard D. Pilnik acquired 7,840 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $2.56 per share, with a total value of $20,070.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

DMAC stock opened at $2.62 on Thursday. The firm has a 50 day moving average of $3.64 and a 200-day moving average of $3.56. DiaMedica Therapeutics Inc has a 12-month low of $2.21 and a 12-month high of $5.93. The company has a current ratio of 12.96, a quick ratio of 12.96 and a debt-to-equity ratio of 0.01.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.07. Sell-side analysts forecast that DiaMedica Therapeutics Inc will post -0.91 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Worth Venture Partners LLC lifted its position in shares of DiaMedica Therapeutics by 10.6% during the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock valued at $657,000 after acquiring an additional 12,651 shares during the period. BlackRock Inc. lifted its position in shares of DiaMedica Therapeutics by 159.7% during the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock valued at $134,000 after acquiring an additional 16,651 shares during the period. Vanguard Group Inc. acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $170,000. Eidelman Virant Capital acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $173,000. Finally, Granite Point Capital Management L.P. acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $1,141,000. Institutional investors own 8.73% of the company’s stock.

A number of equities research analysts recently commented on DMAC shares. Craig Hallum raised their price objective on shares of DiaMedica Therapeutics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Dougherty & Co started coverage on shares of DiaMedica Therapeutics in a research report on Tuesday, April 30th. They issued a “buy” rating and a $8.00 price objective for the company. Zacks Investment Research downgraded shares of DiaMedica Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, ValuEngine upgraded shares of DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. DiaMedica Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.38.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Further Reading: Trade War

Insider Buying and Selling by Quarter for DiaMedica Therapeutics (NASDAQ:DMAC)

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.